Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Ellen K. Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Michael W Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ghulam Warsi, PhD, Carole S. Paley, Ilva Dautaj, Felice P. Lin, PharmD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4050.

https://doi.org/10.1182/blood.V126.23.4050.4050

Published: 2015

Journal Articles

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Robert L. Schlossman, MD, Melissa Alsina, MD, Donna M. Weber, M.D., Steven E. Coutre, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael S. Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole S. Paley, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 1970.

https://doi.org/10.1182/blood.V122.21.1970.1970

Published: 2013

Journal Articles

48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

Roger M. Lyons, MD, Billie J. Marek, MD, Carole S. Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2775.

https://doi.org/10.1182/blood.V122.21.2775.2775

Published: 2013

Journal Articles

Transition From Pediatric To Adult Care Of High Cost Patients In a Medicaid Population With Sickle Cell Disease

Morey A. Blinder, MD, Medha Sasane, BPharm, PhD, Jonathan Fortier, MA, Carole S. Paley, MD, Mei S. Duh, ScD, MPH, Francis Vekeman, MA

Blood (2013) 122 (21): 2927.

https://doi.org/10.1182/blood.V122.21.2927.2927

Published: 2013

Journal Articles

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

Paul G. Richardson, Robert L. Schlossman, Melissa Alsina, Donna M. Weber, Steven E. Coutre, Cristina Gasparetto, Sutapa Mukhopadhyay, Michael S. Ondovik, Mahmudul Khan, Carole S. Paley, Sagar Lonial

Blood (2013) 122 (14): 2331–2337.

https://doi.org/10.1182/blood-2013-01-481325

Published: 2013

Journal Articles

Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD)

Morey A. Blinder, MD, Francis Vekeman, MA, Alex Trahey, BA, Medha Sasane, PhD, Carole S. Paley, MD, Mei Sheng Duh, MPH, ScD

Blood (2011) 118 (21): 338.

https://doi.org/10.1182/blood.V118.21.338.338

Published: 2011

Journal Articles

Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications

Morey A. Blinder, MD, Francis Vekeman, MA, Alex Trahey, BA, Medha Sasane, PhD, Carole S. Paley, MD, Mei Sheng Duh, MPH, ScD

Blood (2011) 118 (21): 12.

https://doi.org/10.1182/blood.V118.21.12.12

Published: 2011

Journal Articles

A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis

Daniel J DeAngelo, MD, PhD, Ayalew Tefferi, MD, Warren Fiskus, PhD, Ruben A. Mesa, MD, Carole S. Paley, MD, Martha Wadleigh, MD, David S. Snyder, MD, Kebede Begna, MD, Michael S. Ondovik, Jessica Rine, Kapil N. Bhalla, MD

Blood (2010) 116 (21): 630.

https://doi.org/10.1182/blood.V116.21.630.630

Published: 2010

Journal Articles

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Stuart L Goldberg, MD, Patricia Giardina, MD, Joan Parkhurst Cain, MD, Deborah Chirnomas, MD, MPH, Jason Esposito, Carole S. Paley, MD, Elliott Vichinsky, MD

Blood (2010) 116 (21): 5155.

https://doi.org/10.1182/blood.V116.21.5155.5155

Published: 2010

Journal Articles

Optimizing the Use of Deferasirox: Evidence of Synergy When Combined with Deferoxamine

Robert W Grady, PhD, Renzo Galanello, MD, Dorothy A Kleinert, NP, MPH, Carole S. Paley, MD, Patricia J. Giardina, MD

Blood (2010) 116 (21): 5163.

https://doi.org/10.1182/blood.V116.21.5163.5163

Published: 2010

Journal Articles

Strategies to Improve Iron Chelation In Thalassemia Patients Poorly Responsive to Deferasirox:

Deborah Chirnomas, MD, MPH, Aleksandra Yakhkind, MS, Carole S. Paley, MD, Ellis J. Neufeld, MD, PhD

Blood (2010) 116 (21): 4279.

https://doi.org/10.1182/blood.V116.21.4279.4279

Published: 2010

NARROW

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

Transition From Pediatric To Adult Care Of High Cost Patients In a Medicaid Population With Sickle Cell Disease

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD)

Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications

A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Optimizing the Use of Deferasirox: Evidence of Synergy When Combined with Deferoxamine

Strategies to Improve Iron Chelation In Thalassemia Patients Poorly Responsive to Deferasirox:

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only